Why would I delete a post that rightly points out industry acquisitions based on multiples of EBITDA?
Of course, an acquirer looks at it through that lens - I guess the argument to that would be, if a larger scale operator can produce the product at a substantially cheaper cost price, why bother paying a premium?
Hard to find a positive way to spin this...
- Forums
- ASX - By Stock
- SCP
- Ann: Quarterly Activities Report & Appendix 4C
Ann: Quarterly Activities Report & Appendix 4C, page-29
Featured News
Add SCP (ASX) to my watchlist
(20min delay)
|
|||||
Last
24.0¢ |
Change
-0.010(4.00%) |
Mkt cap ! $8.371M |
Open | High | Low | Value | Volume |
25.0¢ | 25.0¢ | 20.0¢ | $20.76K | 90.65K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 1000 | 20.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
24.0¢ | 21869 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 1000 | 0.205 |
2 | 8796 | 0.200 |
1 | 9000 | 0.120 |
1 | 90 | 0.046 |
0 | 0 | 0.000 |
Price($) | Vol. | No. |
---|---|---|
0.240 | 21869 | 1 |
0.250 | 159008 | 1 |
0.255 | 6139 | 1 |
0.260 | 16000 | 2 |
0.275 | 7056 | 1 |
Last trade - 16.10pm 15/11/2024 (20 minute delay) ? |
Featured News
SCP (ASX) Chart |
The Watchlist
ACW
ACTINOGEN MEDICAL LIMITED
Will Souter, CFO
Will Souter
CFO
Previous Video
Next Video
SPONSORED BY The Market Online